CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Steve Chapman

Chief Executive Officer and President, Natera, Inc.

Search every verified Steve Chapman interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Steve Chapman, CEO and President of Natera, discussed the company's progress in genetic testing during a July 2025 appearance on CNBC's "Squawk Box," marking ten years since the company went public. He stated that Natera is cash flow positive and has a market cap of approximately $22 billion. Chapman described the company's focus on detecting tiny quantities of DNA across three areas: cancer recurrence, organ rejection, and prenatal care. He explained that Natera's Signatera test sequences a patient's tumor and germline DNA to create a personalized assay that can detect cancer recurrence up to two years before imaging, and noted that the company has processed 12 million tests, with an estimated total addressable market of around $50 billion across its portfolio. In a 2019 interview with Jim Cramer, Chapman outlined Natera's earlier expansion from reproductive health into oncology and organ transplant monitoring. He said the company's prenatal testing business generated nearly $300 million in revenue that year, and discussed efforts to detect colorectal cancer recurrence approximately eight months before imaging, as well as using donor-derived DNA to detect kidney transplant rejection. Chapman also noted that Natera's approach differed from asymptomatic screening, focusing instead on patients already diagnosed with cancer to monitor for recurrence.

Recent appearances

  • Technology helps detect recurrence of cancer through a blood test

    July 09, 2025 · 📺 Fox Business

    Natera CEO Steve Chapman discusses the evolution of the company over ten years and how the company helps cancer patients on 'The Claman Countdown.' #foxbusiness #news #usa #usnews #fox #cancer #cancerawareness #treatment Subscribe to Fox Business: https://bit.ly/2D9Cdse Watch more Fox Business Video: https://video.foxbusiness.com Watch Fox Business Network Live: http://www.foxnewsgo.com/ FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. Headquartered in New York — the business capital of…

    Watch on YouTube ↗

  • Natera CEO on cancer recurrence detection and how it works

    July 08, 2025 · 📺 CNBC Television

    Steve Chapman, Natera CEO, joins 'Squawk Box' to discuss the company's innovative technique, how cancer recurrence ...One of the companies on the leading edge is Natera. Joining us now, Natera CEO Steve Chapman. The company is celebrating ...

    Watch on YouTube ↗

  • TradeTalks: Cell-free DNA diagnostic testing and remote testing capabilities

    June 16, 2021 · 📺 Nasdaq

    Natera CEO Steve Chapman joins Jill Malandrino on Nasdaq #TradeTalks to discuss cell-free DNA diagnostic testing and remote testing capabilities. $NTRA

    Watch on YouTube ↗

  • Natera: Revolutionizing healthcare with generation cell free DNA testing

    March 16, 2021 · 📺 LilaMax Media

    Jane King interviews Steve Chapman, CEO, Natera. https://www.natera.com/ Segment from the TV Show 'Innovators with Jane King'. 'Innovators with Jane King' profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. (FROM COMPANY WEBSITE) Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment. Through our next-generation, cell-free DNA (cfDNA…

    Watch on YouTube ↗

  • Natera CEO: We’re using DNA tech to change disease management

    December 06, 2019 · 📺 CNBC Television

    Jim Cramer chats with Natera CEO Steve Chapman about how the company is growing its reproductive health system and proprietary technology to alter how disease is managed worldwide. Chapman said Natera is changing the way disease is detected using small amounts of DNA. He said the first application of the technology was prenatal testing, which is now a $300 million business. The company is now expanding their research to include oncology and organ rejection. There are currently one million tests a year for colorectal cancer that Natera could tap into, Chapman explained. While 150,000 patient…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →